MarketCap
Facebook
X
TelegramQuarterly report 2024-Q1
added 05-14-2024
Motus GI Holdings Operating Income 2011-2025 | MOTS
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Motus GI Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.9 M | -17.9 M | -17.9 M | -19 M | -23.4 M | -18.9 M | -13 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -11.9 M | -23.4 M | -17.4 M |
Quarterly Operating Income Motus GI Holdings
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.03 M | - | -2.39 M | -2.68 M | -4.36 M | - | -4.7 M | -4.59 M | -4.53 M | - | -4.34 M | -4.59 M | -4.44 M | - | -3.82 M | -4.22 M | -6.71 M | - | -5.42 M | -5.65 M | -6.36 M | - | -5.13 M | -4.13 M | -4.08 M | - | -3.99 M | -2.51 M | -2.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.03 M | -6.71 M | -4.24 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 19.0 | -1.91 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 20.75 | -2.01 % | $ 223 M |  China |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 0.23 | -3.91 % | $ 6.75 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 39.22 | -0.44 % | $ 1.09 B | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 230.27 | -0.02 % | $ 168 B | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 10.22 | 1.79 % | $ 290 M | Israel |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.52 | -0.16 % | $ 1.93 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-876 M | $ 101.55 | -0.02 % | $ 18.8 B | USA |
 |
DexCom
DXCM
|
598 M | $ 68.16 | 0.87 % | $ 26.3 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 26.59 | -0.47 % | $ 804 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-203 M | $ 19.3 | -0.92 % | $ 1.04 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 100.62 | -1.59 % | $ 3.97 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
Anixa Biosciences
ANIX
|
-13.8 M | $ 3.17 | -1.09 % | $ 101 K | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 226.44 | -0.21 % | $ 41.1 B | USA |
 |
Guardant Health
GH
|
-444 M | $ 102.14 | -0.82 % | $ 12.5 B | USA |
 |
Myriad Genetics
MYGN
|
-124 M | $ 6.4 | -1.31 % | $ 580 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 4.66 | -8.27 % | $ 2.5 M | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 7.27 | 1.89 % | $ 1.58 B | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
National Research Corporation
NRC
|
40 M | $ 18.6 | -0.35 % | $ 456 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 27.32 | 0.77 % | $ 20 B |  Niderland |
 |
Personalis
PSNL
|
-68.3 M | $ 8.14 | - | $ 482 M | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | $ 45.94 | 1.26 % | $ 10.2 B | Niderland |
 |
Illumina
ILMN
|
-833 M | $ 134.51 | -0.33 % | $ 21.4 B | USA |
 |
Charles River Laboratories International
CRL
|
227 M | $ 202.78 | -0.43 % | $ 10.4 B | USA |
 |
RadNet
RDNT
|
105 M | $ 72.71 | -0.6 % | $ 5.31 B | USA |
 |
Soleno Therapeutics
SLNO
|
-188 M | $ 47.59 | -0.13 % | $ 1.91 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 175.65 | -0.16 % | $ 19.5 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 6.62 | -2.86 % | $ 858 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.09 B | $ 253.7 | -0.07 % | $ 21.3 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 181.2 | -0.9 % | $ 14.9 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.13 B | $ 687.59 | -0.13 % | $ 56.7 B | USA |
 |
Lantheus Holdings
LNTH
|
457 M | $ 67.17 | 0.69 % | $ 4.65 B | USA |